GDF15 is a potential predictive biomarker for TPF induction chemotherapy and promotes tumorigenesis and progression in oral squamous cell carcinoma

Yang, Cuixia; Ma, Jun; Zhu, Dongwang; Liu, Yahui; Montgomery, Bruce; Wang, L.Z.; Li, J.; Zhang, Z.Y.; Zhang, C.P.; Zhong, Lai‐ping

doi:10.1093/annonc/mdu120

Cited by 60 publications

(57 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…GDF15 has also been reported as a nonspecific biomarker for many diseases, including cancer, cardiac, pulmonary, renal, and gynecological disease (Izumiya et al 2014;Kempf and Wollert 2013;Trovik et al 2014;Yang et al 2014). Since several of these conditions are highly prevalent in m.3243A>G carriers (de Laat et al 2012;Hirano et al 2002), including kidney failure (Breit et al 2012), diabetes mellitus (Dominguez-Rodriguez et al 2014), and cardiomyopathy (Montoro-Garcia et al 2012), the contribution of these conditions to the concentration of GDF15 was studied in more detail.…”

Section: Discussionmentioning

confidence: 99%

“…GDF15 was already known as a quite nonspecific biomarker for cancer, as well as cardiac, pulmonary, renal, and gynecological disease (Izumiya et al 2014;Kempf and Wollert 2013;Trovik et al 2014;Yang et al 2014;Breit et al 2012;Montoro-Garcia et al 2012). However, the concentrations reported in these disorders are within the 1.000-7.000 pg/ mL range (Dominguez-Rodriguez et al 2014;Ho et al 2013;Izumiya et al 2014;Montoro-Garcia et al 2012;Trovik et al 2014), whereas concentrations as high as 85.252 pg/mL were reported in patients with mitochondrial disease (Kalko et al 2014).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Serum GDF15 Levels Correlate to Mitochondrial Disease Severity and Myocardial Strain, but Not to Disease Progression in Adult m.3243A>G Carriers

et al. 2015

View full text Add to dashboard Cite

In this observational cohort study, we examined the prognostic value of growth and differentiation factor 15 (GDF15) in indicating and monitoring general mitochondrial disease severity and progression in adult carriers of the m.3243A>G mutation.Ninety-seven adult carriers of the m.3243A>G mutation were included in this study. The Newcastle mitochondrial disease adult scale was used for rating mitochondrial disease severity. In parallel, blood was drawn for GDF15 analysis by ELISA. Forty-nine carriers were included in a follow-up study. In a small subset of subjects of whom an echocardiogram was available from general patient care, myocardial deformation was assessed using two-dimensional speckle-tracking strain analysis.A moderate positive correlation was found between the concentration of GDF15 and disease severity (r ¼ 0.59; p < 0.001). The concentration of serum GDF15 was higher in m.3243A>G carriers with diabetes mellitus, cardiomyopathy, and renal abnormalities. After a 2-year follow-up, no significant correlation was found between the change in disease severity and the change in the concentration of GDF15 or between the GDF15 level at the first assessment and the change in disease severity. In the subcohort of patients of whom an echocardiogram was available, the concentration of GDF15 correlated moderately to longitudinal global strain (r ¼ 0.55; p ¼ 0.006; n ¼ 23) but not to circumferential or radial strain.Our results indicate that serum GDF15 is not a strong surrogate marker for general mitochondrial disease severity. Its value in indicating myocardial deformation should be confirmed in a prospective longitudinal study.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Serum GDF15 Levels Correlate to Mitochondrial Disease Severity and Myocardial Strain, but Not to Disease Progression in Adult m.3243A>G Carriers

et al. 2015

View full text Add to dashboard Cite

show abstract

“…It is unclear whether the association between aggressive patterns of immunologic markers and poor overall survival in multiple cancer types is attributable to the effects of in injured tissues and during disease processes. It is being investigated as a drug target for delaying the progression of cacs, and it has been found to be a predictor of benefit (overall survival, disease-free survival, locoregional recurrence-free survival, and distant metastasis-free survival) from paclitaxelplatinum-5-flurouracil chemotherapy in oral squamous cell carcinoma 11,12 .…”

Section: Valdes Md* and Mr Chasen Mbchb Mphil(pall Med) †mentioning

confidence: 99%

Tumour Inflammatory Response: Adding Fuel to the Fire?

Valdés

Chasen

2015

Current Oncology

View full text Add to dashboard Cite

show abstract

“…However, as a recent phase II trial (DeCIDE) and a phase III trial (PARADIGM) may have been underpowered to show a survival advantage for TPF induction followed by chemoradiotherapy versus chemoradiotherapy alone [4,5], there is an ongoing debate which subset of patients may benefit from TPF [6,7]. Recently, it has been shown that growth differentiation factor 15 (GDF15) expression can be used as a prognostic biomarker for oral squamous cell carcinoma, and as a predictive biomarker for benefitting from TPF IC [8]. Furthermore, patients with low annexin A1 expression or low p53 expression significantly profited more from TPF IC than patients with high expression of the these oncogenic factors [9,10].…”

Section: Introductionmentioning

confidence: 99%

Parameters of Stromal Activation and Epithelial to Mesenchymal Transition as Predictive Biomarkers for Induction Chemotherapy in Patients With Locally Advanced Oral Cavity and Oropharyngeal Squamous Cell Cancer

Geweiler

Inhestern

Berndt

et al. 2016

Clin Exp Otorhinolaryngol

View full text Add to dashboard Cite

ObjectivesInduction chemotherapy (IC) is likely to be effective for biologically distinct subgroups of oral cancer and biomarker development may lead to identification of those patients.MethodsWe evaluated immune cell infiltration, stroma formation and structure of the invasive front as well as the immunohistochemical expression of alpha smooth muscle actin (ASMA), CD163, E-cadherin, N-cadherin, and the laminin gamma 2 chain in pretreatment biopsy specimens and surgical resections after IC in 20 patients with locally advanced oral cancer who were treated in a prospective, ongoing, phase II trial on IC using docetaxel, cisplatin, and 5-fluorouracil (TPF).ResultsSignificant negative prognostic factors for incomplete pathological tumor response to IC were alcohol abuse (P=0.032), cN+ (P=0.042), and <30% tumor reduction after first cycle of IC (P=0.034). Of the investigated histological parameters and biomarkers only a low membrane-bound expression of E-cadherin showed a trend to be associated with incomplete response to IC (P=0.061). Low expression of ASMA in stromal vessels and a strong tumor invasion front were significantly associated to tumor recurrence (P=0.024 and P=0.004, respectively). The median follow-up of all patients was 35 months. Alcohol abuse (P<0.001), <30% tumor reduction after first cycle of IC (P=0.005), and a strong tumor invasion front (P=0.019) were negative prognostic factors for overall survival.ConclusionA strong predictive biomarker among the investigated parameters for benefitting from TPF IC could not be found. The extent of the tumor invasion front was a negative prognostic marker for recurrence and survival in oral cancer treated by TPF IC followed by surgery and postoperative radiochemotherapy.

show abstract

GDF15 is a potential predictive biomarker for TPF induction chemotherapy and promotes tumorigenesis and progression in oral squamous cell carcinoma

Cited by 60 publications

References 22 publications

Serum GDF15 Levels Correlate to Mitochondrial Disease Severity and Myocardial Strain, but Not to Disease Progression in Adult m.3243A>G Carriers

Serum GDF15 Levels Correlate to Mitochondrial Disease Severity and Myocardial Strain, but Not to Disease Progression in Adult m.3243A>G Carriers

Tumour Inflammatory Response: Adding Fuel to the Fire?

Parameters of Stromal Activation and Epithelial to Mesenchymal Transition as Predictive Biomarkers for Induction Chemotherapy in Patients With Locally Advanced Oral Cavity and Oropharyngeal Squamous Cell Cancer

Contact Info

Product

Resources

About